Posted by Michael Wonder on 26 Oct 2023
ViiV Healthcare receives approval from China’s National Medical Products Administration for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment
26 October 2023 - The marketing authorisation for rilpivirine long-acting injection was received on the 18 October 2023.
GSK announced that ViiV Healthcare announced that the National Medical Products Administration of China has approved ViiV Healthcare’s Vocabria (cabotegravir injection) used in combination with the Janssen's Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection.
